Glenmark settles patent row with Daiichi, Genzyme

NEW DELHI: Glenmark Pharmaceuticals on Monday said it has settled a patent infringement litigation with Daiichi Sankyo and Genzyme, paving way for it to market generic Colesevelam Hydrochloride used for treating diabetes and high cholesterol in the US market.

As per the terms of the settlement, the company has received a licence from Daiichi Sankyo and Genzyme that will permit it to launch its generic Colesevelam Hydrochloride products on April 2, 2015 or earlier under certain circumstances in the US, Glenmark said in a statement.

It, however, did not specify what 'the certain circumstances' were. “Daiichi Sankyo and Genzyme had filed a patent infringement suit in November 2010 in the US District Court for the District of Delaware seeking to prevent Glenmark from commercialising its ANDA prior to expiration of the Orange Book patents,” the company said.

The company and its subsidiaries have settled the litigation with Daiichi Sankyo Inc and Genzyme Corporation regarding its abbreviated new drug application (ANDA) filed with US food and Drug Administration for Colesevelam Hydrochloride, Glenmark said.